摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[(2R,3S,4S)-5-(7,8-二甲基-2,4-二氧代-1,5-二氢苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 | 1910-41-4

中文名称
[(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[(2R,3S,4S)-5-(7,8-二甲基-2,4-二氧代-1,5-二氢苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯
中文别名
——
英文名称
FADH2
英文别名
FAD;10-[(2S,3S,4R)-5-[[[(2R,3S,4R,5R)-5-(6-azaniumylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2,3,4-trihydroxypentyl]-7,8-dimethyl-2-oxo-1,5-dihydrobenzo[g]pteridin-4-olate
[(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[(2R,3S,4S)-5-(7,8-二甲基-2,4-二氧代-1,5-二氢苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯化学式
CAS
1910-41-4
化学式
C27H35N9O15P2
mdl
——
分子量
787.574
InChiKey
YPZRHBJKEMOYQH-UYBVJOGSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    2.09±0.1 g/cm3(Predicted)
  • 物理描述:
    Solid

计算性质

  • 辛醇/水分配系数(LogP):
    -4.8
  • 重原子数:
    53
  • 可旋转键数:
    13
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    356
  • 氢给体数:
    11
  • 氢受体数:
    21

SDS

SDS:ba225fcebce0d08d86e866169e21e8f9
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    青蒿素的亚甲基同系物:意外的结构-活性关系和设计的C10取代青蒿素的可能含义。
    摘要:
    我们试图确定青蒿素的亚甲基同系物是否比青蒿素在生物学上更活泼,更稳定。通过将天然的O和N糖苷转化为可能具有增强的生物活性和稳定性的更稳定的C糖苷来进行类比。将双氢青蒿素转化为10β-氰基-10-脱氧青蒿素,然后将其水解为α-伯酰胺。β-氰化物和α-酰胺的还原提供了各自的甲胺差向异构体,二甲砜处理后分别得到了青蒿素的β-和α-亚甲基同系物。令人惊讶的是,该化合物在体外对恶性疟原虫的活性低于青蒿素。并且对A549,HCT116和MCF7肿瘤细胞系没有明显的活性。可以根据一种针对青蒿素的作用机理的模型,即辅因子模型,来合理化这种活性损失,其中,在细胞内扰动过程中,C10上存在一个离去基团有助于驱动氢化物从还原的黄素辅因子转移至过氧化物。青蒿素的氧化还原稳态。值得注意的是,蒿甲醚的碳水化合物类似物在体外对恶性疟原虫的活性低于邻糖苷母体。,尽管目前尚无法将此类活性差异外推至其他青蒿素。但是,文献数据
    DOI:
    10.1002/cmdc.201600011
  • 作为产物:
    参考文献:
    名称:
    Catalytic reduction of redox-active co-factors and proteins by dihydrogen with sephadex supported platinum clusters as catalysts
    摘要:
    铂碳基簇 [Pt15(CO)30]2– 锚定在 QAE-SEPHADEX 阴离子交换剂上,是一种有效的催化剂,用于还原黄素辅因子、脂肪酰胺脱氢酶和细胞色素 c 氧化酶。
    DOI:
    10.1039/cc9960000207
  • 作为试剂:
    参考文献:
    名称:
    Cyclization of RGD Peptides by Suzuki–Miyaura Cross-Coupling
    摘要:
    Halogenated L- or D-tryptophan obtained by biocatalytic halogenation was incorporated into RGD peptides together with a variety of alkyl or aryl boronic acids. Suzuki-Miyaura cross-coupling either in solution or on-resin results in side chain-to-tail-cyclized RGD peptides, for example, with biaryl moieties, providing a new dimension of structure-activity relationships. An array of RGD peptides differing in macrocycle size, the presence of D-amino acid, N-methylation, or connectivity between the indole moiety and the boronic acid showed that, in particular, connectivity exhibits a major impact on affinities toward integrins, for example, a(v)beta(3). Structure-activity relationship studies yielded peptides with affinities toward a(v)beta(3) in the low nanomolar range, good selectivity, and high plasma stability. Structural characteristics of representative molecules have been investigated by molecular dynamics simulations, which allowed understanding the observed activity differences.
    DOI:
    10.1021/acs.jmedchem.9b00360
点击查看最新优质反应信息

文献信息

  • <i>E. coli</i> Nickel‐Iron Hydrogenase 1 Catalyses Non‐native Reduction of Flavins: Demonstration for Alkene Hydrogenation by Old Yellow Enzyme Ene‐reductases**
    作者:Shiny Joseph Srinivasan、Sarah E. Cleary、Miguel A. Ramirez、Holly A. Reeve、Caroline E. Paul、Kylie A. Vincent
    DOI:10.1002/anie.202101186
    日期:2021.6.14
    A new activity for the [NiFe] uptake hydrogenase 1 of Escherichia coli (Hyd1) is presented. Direct reduction of biological flavin cofactors FMN and FAD is achieved using H2 as a simple, completely atom-economical reductant. The robust nature of Hyd1 is exploited for flavin reduction across a broad range of temperatures (25–70 °C) and extended reaction times. The utility of this system as a simple,
    展示了大肠杆菌 (Hyd1) 的 [NiFe] 摄取氢化酶 1 的新活性。使用H 2作为简单、完全原子经济的还原剂可实现生物黄素辅因子FMN 和FAD 的直接还原。Hyd1 的稳健特性可在较宽的温度范围 (25–70 °C) 和较长的反应时间下还原黄素。该系统作为简单、易于实施的 FMNH 2或 FADH 2再生系统的实用性通过向老黄酶“烯还原酶”提供还原黄素以支持不对称烯烃还原且转化率高达 100% 来证明。在黄素回收过程中记录了Hyd1 周转频率高达 20.4 min -1和总周转次数高达 20 200。
  • Reactions of Antimalarial Peroxides with Each of Leucomethylene Blue and Dihydroflavins: Flavin Reductase and the Cofactor Model Exemplified
    作者:Richard K. Haynes、Kwan-Wing Cheu、Maggie Mei-Ki Tang、Min-Jiao Chen、Zu-Feng Guo、Zhi-Hong Guo、Paolo Coghi、Diego Monti
    DOI:10.1002/cmdc.201000508
    日期:2011.2.7
    argon. Under the same conditions, FADH2 in turn cleanly reduces the antimalarial drug methylene blue (MB) to leucomethylene blue. The latter is rapidly re‐oxidized by artemisinins, thus supporting the proposal that MB exerts its antimalarial activity, and synergizes the antimalarial action of artemisinins, by interfering with redox cycling involving NADPH reduction of flavin cofactors in parasite flavin
    在氩气中,pH 7.4的水性缓冲液中的NADPH-大肠杆菌黄素还原酶(Fre)将黄素腺嘌呤二核苷酸(FAD)还原为FADH 2。在相同条件下,FADH 2依次将抗疟疾药物亚甲基蓝(MB)还原为无色亚乙基蓝。后者被青蒿素迅速重新氧化,从而支持了MB发挥其抗疟活性,并通过干扰寄生虫黄素二硫键还原酶中黄素辅因子的NADPH还原的氧化还原循环,发挥了青蒿素的抗疟作用的提议。直接处理FADH 2在生理条件下,pH 7.4时,青蒿素和抗疟疾活性四恶烷和三恶烷结构类似物从NADPH-Fre-FAD中产生,导致青蒿素快速还原,过氧化物结构类似物有效转化为酮产物。FADH 2氧化相对速率的比较表明三氧戊环的最佳活性。因此,对于三氧戊环而言,寄生内氧化还原扰动的速率将最大,这与其增强的体外抗疟活性有关可能是重要的。使用BNAH-核黄素(RF)模型系统的1 H NMR光谱研究表明,四恶烷能够同时使用两个过氧化物单元来氧化RFH
  • Inductively-powered ring-based sensor
    申请人:Fujitsu Limited
    公开号:EP2457500A1
    公开(公告)日:2012-05-30
    In particular embodiments, a system includes a sensor affixable to a person's body, where the sensor can wirelessly receive power from a power source and wirelessly transmit sensor information to a receiver.
    在具体的实施方案中,系统包括一个可贴在人身上的传感器,传感器可从电源无线接收电能,并将传感器信息无线传输到接收器。
  • Mood sensor
    申请人:Fujitsu Limited
    公开号:EP2479692A2
    公开(公告)日:2012-07-25
    In particular embodiments, a method includes receiving and recording inputs identifying a mood of a person, a mood intensity level of the mood, an activity of the person coinciding with the mood, and time of the mood. The method may be applied to monitoring the psychological state of a smartphone user. A first input identifying a mood of a person; a second input identifying a mood intensity level of the mood; and a third input identifying an activity of the person coinciding with the mood are input and recorded along with a time indication for the first, second, and third inputs.
    在特定实施例中,一种方法包括接收和记录识别人的情绪、情绪强度等级、与情绪相吻合的人的活动和情绪时间的输入。该方法可用于监测智能手机用户的心理状态。第一输入识别人的情绪;第二输入识别情绪的强度级别;第三输入识别与情绪相吻合的人的活动,并记录第一、第二和第三输入的时间指示。
  • Monitoring of musculoskeletal pathologies
    申请人:Fujitsu Limited
    公开号:EP2457501A1
    公开(公告)日:2012-05-30
    In particular embodiments, a method includes accessing data streams from accelerometers or kinesthetic sensors affixed to a person's body, analyzing data sets collected from the person when the person is engaged in various activities, and determining the current musculoskeletal pathology grade of the person.
    在具体的实施方案中,方法包括从贴在人身上的加速度计或运动传感器获取数据流,分析人在从事各种活动时从人身上收集的数据集,并确定人当前的肌肉骨骼病理学等级。
查看更多

同类化合物

腺嘌呤黄素 核黄素磷酸钠 核黄素杂质B 核黄素5'-焦磷酸盐 核黄素4′,5′-二磷酸酯 [5-(6-氨基嘌呤-9-基)-4-羟基-3-膦酰氧基四氢呋喃-2-基]甲基[[5-(7,8-二甲基-2,4-二氧代苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 [5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[5-(7,8-二甲基-2,4-二氧代-6-硫氰酸基苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 [5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[5-(7,8-二甲基-2,4-二氧代-6-硫代-1H-苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 [5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[5-(6-叠氮基-7,8-二甲基-2,4-二氧代苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 [(2S,3R,4R)-5-(7,8-二甲基-2,4-二氧代苯并[g]蝶啶-10-基)-2,3,4-三羟基戊基]磷酸二氢酯 [(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[(2S,3R,4S)-5-(7,8-二甲基-2,4-二氧代苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 [(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-3,4-二羟基四氢呋喃-2-基]甲基[[(2R,3S,4S)-5-(7,8-二甲基-2,4-二氧代-1,5-二氢苯并[g]蝶啶-10-基)-2,3,4-三羟基戊氧基]-羟基磷酰]磷酸氢酯 2,6-蒽二酚 1-脱氧-1-(7,8-二甲基-2,4-二氧代-1,3,4,5-四氢苯并[g]蝶啶-10(2H)-基)-5-O-膦酰戊糖醇 8-formyl-riboflavin-5′-phosphate riboflavin adenine dinucleotide riboflavin 5'-phosphate [[(2R,3S,4R,5R)-3,4-dihydroxy-5-(9H-imidazo[2,1-f]purin-6-ium-3-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate;chloride Riboflavin 5'-monophosphate sodium salt dihydrate Flavin adenine dinucleotide sodium salt 6-Hydroxy-fad Riboflavin 5a(2)-(trihydrogen diphosphate), 4a,5-dihydro-4a-hydroperoxy-, Pa(2)a5a(2)-ester with adenosine Lyxoflavin 5'-monophosphate Pharmakon1600-01505763 7,8-dimethyl-2,4-dioxo-10-[(2R,3S,4R)-2,3,4-trihydroxy-5-phosphonooxypentyl]benzo[g]pteridin-5-ium-5-sulfonic acid [(2R,3S,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate N(5)-sulfo-FADH2 [[(2R,3S,4R,5R)-5-(6-amino-4,5-dihydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,3S,4R,5S)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(7,8-dimethyl-2,4-dioxo-1,5-dihydrobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [(2S,3R,4R)-5-(7,8-dimethyl-2,4-dioxo-1,5-dihydrobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate [5-(8-Cyano-7-methyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate [(3S)-1-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-3-oxo-1,2,3lambda5-dioxaphosphiran-1-ium-3-yl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-ium-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [(2R,3S,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate [[(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [(E)-3-[10-[(2S,3S,4R)-5-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2,3,4-trihydroxypentyl]-7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-5-yl]prop-2-enylidene]-benzyl-methylazanium [(2R,3R,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate [(2R,3R,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate [(2R,3R,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate [[(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4R)-5-[7,8-dimethyl-5-(2-methylpropanoyl)-2,4-dioxobenzo[g]pteridin-5-ium-10-yl]-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-5-[7,8-dimethyl-5-[(E)-3-[methyl-[(2R)-1-phenylpropan-2-yl]amino]prop-1-enyl]-2,4-dioxo-1H-benzo[g]pteridin-10-yl]-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-2,3,4-trihydroxy-5-[5-[3-[[(1R)-6-hydroxy-2,3-dihydro-1H-inden-1-yl]imino]propyl]-7,8-dimethyl-2,4-dioxo-1H-benzo[g]pteridin-10-yl]pentyl] hydrogen phosphate [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4R)-5-(7,8-dimethyl-2,4,6-trioxo-1H-benzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [(2R,3S,4S)-2,3,4-trihydroxy-5-(11,12,14,14-tetramethyl-3,5-dioxo-1,4,6,8-tetrazatetracyclo[7.7.1.02,7.013,17]heptadeca-2(7),9(17),10,12,15-pentaen-8-yl)pentyl] dihydrogen phosphate [(2R,3S,4S)-5-[7,8-dimethyl-5-(3-methylbutyl)-2,4-dioxo-1H-benzo[g]pteridin-10-yl]-2,3,4-trihydroxypentyl] dihydrogen phosphate [[(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate [[(2R,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-[(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentoxy]-oxophosphanium